AI-generated summary
The authors randomized 26 adults with mild cognitive impairment due to Alzheimer's disease to self-administered at-home transcranial photobiomodulation or sham for 12 weeks. The treatment group showed a statistically significant improvement in one cognitive test (K-MoCA) at week 13 compared with sham, while the MMSE2 change was not significant. No serious adverse events were reported.
- Participants
- 26
- Who or what was studied
- Adults with mild cognitive impairment due to Alzheimer's disease (K-MMSE2 score 23-27, global CDR 0.5-1.0)
- Limits stated in the abstract
- The abstract reports a small sample of 26 participants and does not state wavelengths, so the conclusion that tPBM is effective and safe goes beyond what this limited trial can establish.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Mild cognitive impairment, Photobiomodulation, Sham, Montreal Cognitive Assessment, Dementia, Adenosine triphosphate, Cerebral blood flow. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.